SETD2 and lymphoma: Although guadecitabine is no longer being developed for myeloid disease, the recent registration of an orally available decitabine formulation [42] provides an alternative and convenient backbone for future studies in biologically rational PTCL subgroups including tTFH and SETD2 mutated lymphoma.